MLH1 Promoter Methylation Analysis

Last Modified: 10/5/2023 4:24:55 PM


Medical Necessity Documentation:  
Client Notes:  
Patient Preparation:  
Specimen Requirements:

FFPE tissue: Paraffin block
Collection Instructions: Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Transport & Storage: Temperature/Stability:  
Reference Range: Refer to Interpretive Results
Critical Ranges:  
Test Comments:  
Methodology: Molecular
Clinical Significance:

MLH1 promoter methylation analysis is useful to distinguish sporadic from inherited colorectal and endometrial cancers in tumors that are MLH1-deficient by IHC staining and/or have high levels of microsatellite instability (MSI-H). The majority of MSI in sporadic cases of these tumors is caused by MLH1 promoter hypermethylation, while hypermethylation is rare in inherited cases. MLH1 promoter methylation analysis results should be considered with other clinical risk factors in determination of likelihood of HNPCC/Lynch Syndrome.
Documentation:  
Custom Panel: No

PRODUCTION SCHEDULE

Turn Around Time: 10 to 11 days
Sites Performed: NeoGenomics
PHL Test Code: PS
EPIC Test Code: N/A
Send Out Test Code: Soft Path - MLH1
Alternate Test Names: MLH1 Methylation
Included Tests:  
CPT Coding: 81288

Go back to the top of the page.